Analyst Ratings For Assembly Biosciences Inc (NASDAQ:ASMB)
Today, Assembly Biosciences Inc (NASDAQ:ASMB) stock received an upgrade by B. Riley from Neutral to Buy with a price target of $42.00.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Assembly Biosciences Inc (NASDAQ:ASMB) is Buy with a consensus target price of $60.25 per share, a potential 126.08% upside.
Some recent analyst ratings include
- 10/8/2018-Assembly Biosciences Inc (NASDAQ:ASMB) gets upgraded to Buy by B. Riley with a price target of $42.00
- 8/8/2018-Assembly Biosciences Inc (NASDAQ:ASMB) has coverage initiated with a Outperform rating and $74.00 price target
- 4/13/2018-Assembly Biosciences Inc (NASDAQ:ASMB) gets downgraded to Neutral by Chardan Capital with a price target of $50.00
Recent Insider Trading Activity For Assembly Biosciences Inc (NASDAQ:ASMB)
Assembly Biosciences Inc (NASDAQ:ASMB) has insider ownership of 18.20% and institutional ownership of 65.21%.
- On 9/6/2018 Uri A. Lopatin, Insider, sold 15,540 with an average share price of $40.09 per share and the total transaction amounting to $622,998.60.
- On 9/5/2018 Uri A. Lopatin, VP, sold 15,204 with an average share price of $40.09 per share and the total transaction amounting to $609,528.36.
- On 7/19/2018 Derek A Small, CEO, bought 2,400 with an average share price of $41.48 per share and the total transaction amounting to $99,552.00.
- On 7/2/2018 William R Ringo, Director, sold 1,000 with an average share price of $38.50 per share and the total transaction amounting to $38,500.00.
- On 6/1/2018 William R Ringo, Director, sold 1,000 with an average share price of $42.47 per share and the total transaction amounting to $42,470.00.
- On 5/1/2018 William R Ringo, Director, sold 1,000 with an average share price of $43.06 per share and the total transaction amounting to $43,060.00.
- On 4/2/2018 William R Ringo, Director, sold 1,000 with an average share price of $49.32 per share and the total transaction amounting to $49,320.00.
About Assembly Biosciences Inc (NASDAQ:ASMB)
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Recent Trading Activity for Assembly Biosciences Inc (NASDAQ:ASMB)
Shares of Assembly Biosciences Inc closed the previous trading session at 26,65 −1,28 4,58 % with 25.9 shares trading hands.
